PT UBC Medical Indonesia Tbk (IDX:LABS)
Indonesia flag Indonesia · Delayed Price · Currency is IDR
126.00
+3.00 (2.44%)
May 14, 2025, 11:48 AM WIB

IDX:LABS Income Statement

Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Revenue
147,637136,69993,292129,960
Revenue Growth (YoY)
8.00%46.53%-28.21%-
Cost of Revenue
90,88282,13556,13680,529
Gross Profit
56,75554,56437,15649,431
Selling, General & Admin
47,41248,55836,03343,743
Operating Expenses
47,80348,72033,75846,240
Operating Income
8,9525,8443,3983,191
Interest Expense
-3,041-2,153-1,554-112.31
Interest & Investment Income
212.161.9523.7463.25
Earnings From Equity Investments
--1,122-
Currency Exchange Gain (Loss)
-1,289501.88-1,203-906.66
Other Non Operating Income (Expenses)
315.581,093-72.19245.6
EBT Excluding Unusual Items
5,1505,2871,7132,481
Gain (Loss) on Sale of Investments
-882.29--
Gain (Loss) on Sale of Assets
139.9361.822,814201.48
Pretax Income
5,2906,2314,5282,682
Income Tax Expense
2,3374,0411,6932,374
Earnings From Continuing Operations
2,9522,1902,834308.25
Minority Interest in Earnings
-0.020.020-
Net Income
2,9522,1902,834308.25
Net Income to Common
2,9522,1902,834308.25
Net Income Growth
34.84%-22.75%819.43%-
Shares Outstanding (Basic)
3,9502,354--
Shares Outstanding (Diluted)
3,9502,354--
Shares Change (YoY)
67.78%---
EPS (Basic)
0.750.93--
EPS (Diluted)
0.750.93--
EPS Growth
-19.63%---
Free Cash Flow
-20,490-34,233-18,327-32,341
Free Cash Flow Per Share
-5.19-14.54--
Gross Margin
38.44%39.91%39.83%38.04%
Operating Margin
6.06%4.28%3.64%2.46%
Profit Margin
2.00%1.60%3.04%0.24%
Free Cash Flow Margin
-13.88%-25.04%-19.65%-24.88%
EBITDA
21,11415,40212,18711,009
EBITDA Margin
14.30%11.27%13.06%8.47%
D&A For EBITDA
12,1629,5598,7897,818
EBIT
8,9525,8443,3983,191
EBIT Margin
6.06%4.28%3.64%2.46%
Effective Tax Rate
44.19%64.86%37.40%88.51%
Advertising Expenses
1,1541,123244.61,268
Source: S&P Global Market Intelligence. Standard template. Financial Sources.